Akorn Inc

Akorn — Investor Presentation (September 2014)

22 slides from Akorn's investor presentation, Sep 12, 2014

  1. Slide 1: Q3 2014 Investor Presentation

    @AKORN ADVANCING THE NEW VISION 0@@ Akorn, Inc. Nasdaq: AKRX Q3 2014 Investor Presentation September 2014

  2. Slide 2: Disclaimer

    0o@o @AKORN DISCLAIMER Reform Act of 1995. forecasts of our future sales.

  3. Slide 3: Company Overview: Who We Are

    Ove @AKORN COMPANY OVERVIEW Who We Are... y ane ni and focus on niche dosage forms injectables, ophthalmics, oral liquids, nasal sprays and topical creams and ointments products $256 $86 $137 2010 © 2011-2012. 2018S 2014E $1 Billion addressable market of over $8.7bn % Over 1,500 employees oe Distrib

  4. Slide 4: Market

    o@ ® MARKET Generic market opportunity remains strong. (generics ~84% of Rx volume) position as a key generics player Elevated scrutiny on both regulatory environment & approval process growth Over 80 drugs currently on ee rane ject list, majority are stet market Globalization provides new oneeumeee

  5. Slide 5: Strategic 3-5 Year Goals

    Ove @AKORN STRATEGIC 3-5 YEAR GOALS ay Be #1 in generic ophthalmics afb wel] ~~ E bon Car; 30 countries Sy} Become a $1 billi

  6. Slide 6: Strategic Priorities: Integrate, Develop, Execute, Build

    @@ STRATEGIC INTEGRATE DEVELOP Recel EXECUTE ecent New India Acquisitions Strategy = Leverage scale and ever iferien * Tapin sterile Gea pture synergies Private label ats Leverage new manufacturing capacity BUILD Brand Platform infrastructure

  7. Slide 7: Proven Acquisition Strategy

    00@ Sem PROVEN ACQUISITION STRATEGY | 2011 2012 2013 2014 2015 | ee ——. ac Branded Ophthalmic Portfolio OPHTHALMOLOGY Ftaape Este CosopePE AzaSrre BETIMOL ZiOPTAN: raneonTee Neale nie smash (SU ne toate MANUFACTURING capacrry K<l /@aKorn inde ote sano salt CESS TO OTHER GEOGRAPHIES LEVERAGE INFRASTR

  8. Slide 8: Hettlingen Pending Acquisition

    0o@o HETTLINGEN PENDING ACQUISITION Hettiingen, Switzerland Facility Background Acquisition Details e Jan’15 © CHF 21.7 million ($24 million) orn Located 30 km north of Zurich FDA approved since 2008 600 8 > z Capabilities include ophthalmic solutions, r suspensions, gels, and ointments

  9. Slide 9: Integration Plan

    0o@o INTEGRATION PLAN INTEGRATE Consolidate corporate v functions Implement Akorn Qualit E F 2 u Q4 2014 Policy Implement Akorn standard ERP system 04 2014 Consolidate warehousing nee and distribution Optimize capacity across 4 F 2016 sterile ophthalmic plants Implement. 1 2015 R&D strategy e $20 MM

  10. Slide 10: Continued Investment in R&D

    00e i= same CONTINUED INVESTMENT IN R&D scoer v AKORN R&D SPE! ma($mm) + —*=% of Revenue Y Capabilities = Injecta = Ophthalmies — Topicals — Nasal Sprays = Oral Liquids v 2010 2011 «2012 «2013-2014 ¥ NUMBER OF ANDAs FILED. targets Paragraph IV products 18 PIV Challenges Hi-Tech MVP. mi Akorn 2 25 v

  11. Slide 11: Maturing Pipeline

    0o@o MATURING PIPELINE DEVELOP Aging of ANDA Filings Pending: 87 Tentative: 6 oto6 6to12 —-12to 241036 Over 36 months 18 18to2 Months Since Filing le d mTentative

  12. Slide 12: Develop

    0o@ > DEVELOP Generic Name Market $M (Strength) Brand (# of Competitors) Tobramycin Inhalation = $272 (300MG/SML) " @) Zoledronic Acid IV a $140 ia (5MG/100ML) (5) Dronabinol Oral Capsule Macnet $133 @D (2.5/5/10MG) (4) Zoledronic Acid IV $100 al (4MG/5ML) Zometa 8) () Gatifloxacin Ophthalmic Drops.

  13. Slide 13: India Regulatory Approvals

    00@ i | INDIA REGULATORY APPROVALS y : 7 i US FDA TIMELINE + Incremental staffing * Training initiatives Compliance management (toa product transfes) vy US FDA Filing Timeline f (Tech transfer acquired existing NDA product + Followed by three other filings mid-2014 (Dewiop ANDR product) (Oevelop Ato

  14. Slide 14: Leverage India Infrastructure

    EXECUTE 0o@o LEVERAGE INDIA INFRASTRUCTURE EXPANDED INJECTABLE CAPACITY FOR US/ROW. 2009 2012 2015 Akorn India’s manufacturing capacity allows Akorn to become a significant player in the addressable global injectable market ible Capacity (millions of units) MUS — Hindia_—_m Total Capacity

  15. Slide 15: Branded Ophthalmology Platform

    0o@ BRANDED OPHTHALMOLOGY PLATFORM BUILD physician relationships strategy — Broadens existing platform that includes TheraTears, Akten, and IC Gre 2014

  16. Slide 16: Financial Performance

    @@@ | FINANCIAL PERFORMANCE

  17. Slide 17: Financial Momentum

    0o@o @AKORN FINANCIAL MOMENTUM All Value millions, except EPS REVENUE ADJUSTED EBITDA ADJUSTED EPS $580-600 $230 -240 $1,00-1.05 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 2% CAGR (’10-14) 83% CAGR (10-14)

  18. Slide 18: Strong Balance Sheet & Free Cash Flow

    0o@o @AKORN STRONG BALANCE SHEET & FREE CASH FLOW Cash from Operations (mm) Strong Financial Position ¥ Improving cash flow gen: v poi synerey achievement with Hi-Tech v close in mid-August) $1.1 billion Term Loan B; 4.3x leverage at VersaPharm clos Total long-term leverage objective of 2.0-2.5x Cap

  19. Slide 19: Investment Highlights

    0o@ @AKORN INVESTMENT HIGHLIGHTS Attractive industry dynamics = Acquisiti : attractive niche categories 0 products in Generics make-up profitability and Proven execution cahilaw infrastructure provements . dit ly wit . Clear strategy for 7 . sustained growth = Acquisitions / |

  20. Slide 20: Advancing the New Vision

    (YAKORN Fe ee ll a @ ADVANCING THE NEW VISION

  21. Slide 21: Robust R&D Pipeline Details (US Market)

    @AKORN ROBUST R&D PIPELINE DETAILS (US MARKET) Number of Pipeline Products by Category (with Market Opportunity in millions) Number of Pipeline Products by Specialty (with Market Opportunity in millions) Filed To Be Filed Ophthatmic Injecable 20 30 Filed To Be Filed Filed) Total lue_Count 5,020 38)

  22. Slide 22: Maturing Pipeline

    0o@o @AKORN MATURING PIPELINE Aging of ANDA Filings by Segment Total Filed: 93 (Tentative Approvals: 6) 2atess over 36 oaths 4 06 = Storz_—sa2to 8 1st028 8 Since Filing Month [[ophtianie minectabie moter Market Value of Filed ANDAs 3250) Sto 12 $953 I sss2 121018 18to24 24103 Months Since Filing Gen

Akorn — Investor Presentation (September 2014) on 6ix